AURA

Aura Biosciences, Inc.

Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develops AU-011 in additional ocular oncology indications, including choroidal metastases. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.

Aura Biosciences, Inc. (AURA) is rated C (2.4/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Growth (D+). The rating has held at C for 11 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.4 / 5.0
C
Value
C+
Factor Score 2.5 / 5.0
Growth
D+
Factor Score 1.8 / 5.0
Profitability
C+
Factor Score 2.6 / 5.0
Momentum
C
Factor Score 2.4 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -3.6
EV / EBITDA -3.3
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -11.5%
Price Return 12M 30.6%
Catalyst Signal 0.00
Market Cap $751.4M
TTM Revenue N/A
Price / Sales N/A
ROE -61.7%

Historical Factor Score Progression

Held C for 11 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-17 C+ (2.5) D+ (1.8) C+ (2.6) C (2.4) C+ (2.6) C (2.4)
2026-11-10 C+ (2.5) C- (1.9) C+ (2.6) C+ (2.6) C+ (2.6) C (2.4)
2026-11-03 C+ (2.5) D+ (1.8) C+ (2.6) C (2.2) C+ (2.7) C (2.4)
2026-10-27 C+ (2.5) C- (1.9) C+ (2.6) C (2.3) C+ (2.6) C (2.4)
2026-10-20 C+ (2.5) D+ (1.8) C+ (2.6) C (2.4) C+ (2.6) C (2.4)
Page 1 of 4